Bristol Myers: FDA to study Abecma as a treatment for myeloma
As a reminder, Abecma was recently approved in Japan for patients with relapsed or refractory multiple myeloma who have received at least two prior treatments.
Abecma has also received a positive opinion for marketing authorization from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Abecma's regulatory submissions for this patient population remain under review by the EMA and Swissmedic.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction